Lixazinone

Lixazinone (0.5-1 μM; 5 min at 30 °C) potently and selectively inhibits human platelet PDE3, with 0.5 μM causing 97% inhibition of PDE3 activity and minimal effect on PDE2 activity at 1 μM^[1].
Lixazinone (1 μM; 1 min at 37 °C) increases [³H]cAMP levels in human platelets by 177%^[1].
Lixazinone (1 μM; 1 min at 37 °C pre-incubation) fully inhibits thrombin-induced aggregation in human platelets^[1].
Lixazinone (1 μM; 1 min at 37 °C) moderately increases [³H]cAMP levels in human platelets treated with 20 nM PGI₂^[1].
Lixazinone (300 nM; 15 min dark at 0°C, 15 min UV irradiation) inhibits photolabelling of the 115 kDa PDE III subunit in rat platelet lysate and rat heart homogenate^[2].
Lixazinone (10 μM; 60 min) increases intracellular cAMP levels by 22% in quiescent MDCK cells^[3].
Lixazinone (10 μM) activates PKA by 27% in transfected quiescent MDCK cells^[3].
Lixazinone (10 μM; 72 hrs) significantly stimulates mitogenesis in quiescent MDCK cells, as measured by [³H]-thymidine incorporation^[3].
Lixazinone (10 μM; 5 mins) significantly activates B-Raf kinase activity, with no effect on Raf-1 kinase activity, in quiescent MDCK cells^[3].
Lixazinone (10 μM; 1 hr) increases ERK kinase activity by 810% in quiescent MDCK cells^[3].
Lixazinone (10 μM; 4 hrs) stimulates cyclin D kinase activity by 83% and cyclin E kinase activity by 58% in quiescent MDCK cells^[3].
Lixazinone (10 μM; 8 hrs) does not significantly alter expression of p21 or p27 in quiescent MDCK cells^[3].
Lixazinone (10 μM; 24 hrs) potently inhibits mitogenesis in rat glomerular mesangial cells, as measured by [³H]-thymidine incorporation^[3].
Lixazinone (1 nM-10 μM) inhibits cAMP phosphodiesterase activity in total homogenates of cultured primary rat mesangial cells with an IC₅₀ of 2.85 nM, a potency that correlates with its suppression of mitogenesis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.